Your browser doesn't support javascript.
loading
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.
Burger, Jan A; Barr, Paul M; Robak, Tadeusz; Owen, Carolyn; Ghia, Paolo; Tedeschi, Alessandra; Bairey, Osnat; Hillmen, Peter; Coutre, Steven E; Devereux, Stephen; Grosicki, Sebastian; McCarthy, Helen; Simpson, David; Offner, Fritz; Moreno, Carol; Dai, Sandra; Lal, Indu; Dean, James P; Kipps, Thomas J.
Afiliação
  • Burger JA; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA. jaburger@mdanderson.org.
  • Barr PM; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
  • Robak T; Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland.
  • Owen C; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
  • Ghia P; Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy.
  • Tedeschi A; ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Bairey O; Rabin Medical Center, Petah Tikva, Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Hillmen P; The Leeds Teaching Hospitals, St. James Institute of Oncology, University of Leeds, Leeds, UK.
  • Coutre SE; Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA, USA.
  • Devereux S; Kings College Hospital, NHS Foundation Trust, London, UK.
  • Grosicki S; Department of Hematology and Cancer Prevention, Silesiam Medical University, Katowice, Poland.
  • McCarthy H; Royal Bournemouth General Hospital, Bournemouth, UK.
  • Simpson D; North Shore Hospital, Auckland, New Zealand.
  • Offner F; Universitair Ziekenhuis Gent, Gent, Belgium.
  • Moreno C; Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
  • Dai S; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
  • Lal I; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
  • Dean JP; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
  • Kipps TJ; UCSD Moores Cancer Center, San Diego, CA, USA.
Leukemia ; 34(3): 787-798, 2020 03.
Article em En | MEDLINE | ID: mdl-31628428
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Leucemia Linfocítica Crônica de Células B Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Leucemia Linfocítica Crônica de Células B Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos